Irbesartan-d4 – 1 mg

Brand:
Cayman
CAS:
1216883-23-6
Storage:
-20
UN-No:
Non-Hazardous - /

Irbesartan-d4 is intended for use as an internal standard for the quantification of irbesartan (Item No. 11952) by GC- or LC-MS. Irbesartan is an antagonist of the angiotensin II type 1 (AT1) receptor (Ki = 1.3 nM).{21001} It is an insurmountable antagonist of AT1, as its antagonism cannot be overcome by increasing concentrations of angiotensin II.{21393} Irbesartan (3, 10, and 30 mg/kg) reduces blood pressure in stroke-prone spontaneously hypertensive rats and increases survival of SPSH rats fed a high-salt low-protein diet.{43281} It also reduces plaque formation, collagen content, as well as the increased expression of the AT1 receptor, PDGF-b, MCP-1, and VCAM-1 in a model of diabetes-induced atherosclerosis using apolipoprotein E (ApoE) knockout mice with diabetes induced by streptozotocin (STZ; Item No. 13104).{43280} Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.  

 

Available on backorder

SKU: 25509 - 1 mg Category:

Description

An internal standard for the quantification of irbesartan by GC- or LC-MS


Formal name: 3-((2′-(2H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl-2,3,5,6-d4)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one

Synonyms: 

Molecular weight: 432.6

CAS: 1216883-23-6

Purity: ≥99% deuterated forms (d1-d4)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Atherosclerosis||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes